BiotechTube
aVaxziPen

aVaxziPen

Oxford, United Kingdom· Est.
avaxmed.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

aVaxziPen is pioneering a solid-dose, needle-free vaccine delivery system designed to address major challenges in global immunization. Its platform offers significant advantages including enhanced thermostability (up to 50°C for 12 months), dose-sparing potential (e.g., 9-fold antigen reduction demonstrated for influenza), and the elimination of needles, sharps waste, and cold chain dependencies. Founded in 2017 and led by a team with deep pharmaceutical industry experience, the company is positioned to improve vaccine access, economics, and safety worldwide.

Infectious Disease

Technology Platform

Needle-free solid-dose vaccine delivery platform creating thermally stable (up to 50°C), highly immunogenic, rice-grain-sized formulations that dissolve rapidly upon administration, enabling dose-sparing and cold chain elimination.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The platform addresses massive unmet needs in global vaccine access by potentially eliminating the cold chain, enabling significant dose-sparing to stretch manufacturing capacity, and improving safety/compliance via needle-free administration.
This creates opportunities in pandemic preparedness, routine immunization in low-resource settings, and niche markets like veterinary vaccines or allergy immunotherapy.

Risk Factors

Key risks include unproven clinical translation of preclinical thermostability and immunogenicity data, complex regulatory pathways for a novel combination product, challenges in scaling GMP manufacturing, and competition from other next-generation delivery technologies.
The pre-revenue, partnership-dependent business model carries significant execution and financial risk.

Competitive Landscape

aVaxziPen competes in the alternative vaccine delivery space against companies developing microarray patches (e.g., Vaxxas, Micron Biomedical), nasal sprays, jet injectors, and other solid-dose/oral formulations. Its claimed differentiators are the combination of high thermostability, strong immunogenicity, and dose-sparing in a rapid-dissolve solid dose. It also indirectly competes with established adjuvants and formulation technologies aimed at improving vaccine stability and potency.

More companies in Drug Delivery & Formulation →More companies in United Kingdom →